Nornicotine

Drug Profile

Nornicotine

Latest Information Update: 09 Dec 2010

Price : $50

At a glance

  • Originator Yaupon Therapeutics
  • Class Alkaloids; Nicotine replacement therapy; Small molecules
  • Mechanism of Action Nicotinic receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Neuropathic pain; Smoking withdrawal

Most Recent Events

  • 09 May 2009 Pharmacodynamics data from a preclinical trial in Neuropathic pain presented at the 28th Annual Scientific Meeting of the American Pain Society (APS-2009)
  • 20 Nov 2007 Pharmacodynamics data presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)
  • 02 Feb 2005 Nornicotine is available for licensing (http://www.yaupontherapeutics.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top